Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 15/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465912 | 0.91 | CYP19A1 (0.55) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL1040778 | 0.84 | CYP19A1 (0.48) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL3465956 | 0.83 | CYP19A1 (0.53) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL3466178 | 0.81 | CYP19A1 (0.60) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL1129307 | 0.80 | AVPR1A (0.39) | CYP19A1CYP11B2 | |
| SCHEMBL3465175 | 0.80 | CYP19A1 (0.56) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL13564610 | 0.79 | CYP19A1 (0.58) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL3464444 | 0.78 | CYP19A1 (0.52) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL3464954 | 0.77 | CYP19A1 (0.53) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL3464627 | 0.74 | CYP19A1 (0.64) | CYP19A1CYP11B2CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071774-B2 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-8071774-B2 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-8071774-B2 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| EP-1896481-B1 | HETEROCYCLIC SPIRO-COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-01-14 | — | — | US | disclosed |
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-01-14 | — | — | US | disclosed |
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-01-14 | — | — | US | disclosed |
| WO-2006128851-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006128852-A2 | HETEROCYCLIC SPIRO-COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP19A1 37/4885CYP11B2 4/4885CYP11B1 2/4885 |
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | REN, NR3C2, CYP21A2 | CYP19A1 67/4885CYP11B2 15/4885CYP11B1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.